FDA One-Day Inspections: What Your Facility Should Know

FDA announced it is piloting a new inspection format it calls the one-day inspectional assessment, described as part of a broader push to make the agency's inspectional resources "more targeted and efficient" (FDA press announcement). I've spent a good portion of my career on both sides of the inspection table, and my first reaction to this kind of announcement is never "great, one less day of disruption." It's "what is FDA optimizing for, and does my facility's quality system actually hold up if the visit gets shorter and the scrutiny gets sharper?"

Those are different questions, and the difference matters. A shorter inspection window doesn't mean a lighter one. It usually means FDA has done more homework before showing up, and expects your facility to prove its case faster than it would have had to in a traditional multi-day surveillance inspection. Let me walk through what this pilot actually appears to change, what the legal and regulatory scaffolding underneath it already allows, and what I'd be doing right now if I ran quality at a regulated facility.

What FDA Actually Announced

FDA's announcement frames the one-day assessment as an addition to its inspection toolkit, not a wholesale replacement for the multi-day surveillance inspections and pre-approval inspections (PAIs) that manufacturers already know. The stated goal is to let FDA touch more facilities with the inspectional hours it has, rather than spending three, four, or five days at a single site every time.

That framing lines up with a pressure FDA has been under for years: more registered facilities, more product categories requiring oversight, and a finite pool of trained investigators. Congress addressed part of this pressure back in 2012. Section 705 of the Food and Drug Administration Safety and Innovation Act (FDASIA) amended the Federal Food, Drug, and Cosmetic Act to require that drug manufacturing establishments — foreign and domestic alike — be inspected according to a risk-based schedule rather than a fixed calendar interval. FDASIA eliminated the old rule that required foreign drug facilities to be inspected only when resources allowed, and required parity in how domestic and foreign sites get prioritized. The one-day assessment looks like the next iteration of that same logic: if risk-based scheduling tells FDA where to look, a shorter, more surgical inspection format tells FDA how to look at more of those places without expanding headcount.

In my view, that's a rational response to a real constraint. It is also a format that rewards facilities with genuinely mature quality systems and punishes facilities that have been getting by on the assumption that a multi-day inspection gives them time to locate documents, brief staff, or "find" a corrective action that was supposed to be closed eight months ago.

One scoping detail from FDA's own release is worth stating plainly, because it changes who should read the rest of this piece with urgency: the pilot "does not apply to higher-risk or more complex facilities that require more comprehensive inspectional coverage." If your site falls into that category, the standard multi-day surveillance inspection is still the one to prepare for, not the compressed format described below — everyone else should keep reading.

The Legal Basis Hasn't Changed — Only the Clock Has

It's worth being precise about what actually shifts here, because the underlying inspection authority is not new. Section 704(a)(1) of the FD&C Act gives FDA investigators the authority to enter and inspect, at reasonable times and within reasonable limits, any factory, warehouse, or establishment where food, drugs, devices, or cosmetics are manufactured, processed, packed, or held for introduction into interstate commerce. That authority doesn't scale up or down based on how many hours the investigator plans to be on site. A one-day assessment operates under the same Section 704 authority as a five-day surveillance inspection.

What changes is scope and preparation on FDA's side. A shorter visit means the investigator has almost certainly narrowed the inspection plan before arriving — focusing on specific systems, specific product lines, or specific issues flagged by import data, complaint trends, or prior inspection history — rather than working through the full battery of subsystems a traditional Quality System Inspection Technique (QSIT) review or general GMP surveillance inspection would cover. If your facility's Corrective and Preventive Action (CAPA) system was going to be reviewed lightly on day four of a five-day inspection, it may now be the entire focus of a one-day visit, because FDA picked that system in advance for a reason.

The same outcome mechanics apply regardless of format. At the conclusion of any inspection — one day or five — the investigator classifies the visit as No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI), using FDA's own post-inspection classification framework. A Form FDA 483 is issued under Section 704(b) when the investigator observes conditions that, in their judgment, may constitute violations. The form itself doesn't carry legal force, but a weak or late response to it is one of the more direct paths to a warning letter I've seen in practice. Compressing the inspection into one day doesn't compress your obligation to respond to a 483 well — if anything, it raises the stakes on getting that response right the first time, since a shorter inspection likely means less accumulated rapport and fewer informal opportunities to walk back a misunderstanding on the floor before it becomes a written observation.

Why This Matters More in 2026 Than It Would Have a Few Years Ago

Timing is part of why I think this pilot deserves attention beyond a quick trade-press mention. Device manufacturers are living through the most significant regulatory overhaul in a decade: the Quality Management System Regulation (QMSR) final rule, published February 2, 2024, replaced the legacy 21 CFR Part 820 Quality System Regulation with a framework that incorporates ISO 13485:2016 by reference, and the compliance date landed on February 2, 2026 — this past February. Every device firm inspected today is being measured against that harmonized framework, whether the inspection lasts one day or five.

FDA's pilot announcement doesn't name QMSR specifically — it describes scope only in terms of "medical products" broadly — but based on where I'd expect scrutiny to land for device makers right now, a shorter inspection window against a newly effective regulatory framework is not a neutral combination. Investigators are still building institutional familiarity with how QMSR nonconformities map onto the old Part 820 subsystem language inspectors have used for years. If your facility hasn't fully mapped its own procedures from the legacy QSR structure to the ISO 13485:2016 clause structure, a one-day assessment gives you very little runway to explain the mapping verbally while the investigator is standing in your document control area.

For drug manufacturers, I'd expect the equivalent pressure point to be 21 CFR Part 211, though FDA's release doesn't name specific regulations by pilot. A one-day assessment focused on, say, laboratory controls under 21 CFR 211.160 or production record review under 211.188 would leave little room for the kind of "let me pull that batch record from archive, give us until tomorrow morning" accommodation that a multi-day inspection sometimes allows. Retrieval speed would become part of the audit itself.

How a One-Day Assessment Likely Differs From What You've Seen Before

The last row is the one I'd flag hardest to a client. A multi-day inspection gives your team informal slack to regroup overnight; a one-day visit generally doesn't. FDA's release notes that investigators retain the authority to extend an assessment when significant observations emerge — and some of the roughly 46 pilot inspections run so far reportedly did — but that's a contingency, not something to plan around. Whatever your facility's front line — the people actually walking the investigator through the floor — knows and can produce in real time is what the record will most likely reflect.

What This Means for Your Facility

I'd break the practical implications into three buckets:

1. Document retrieval speed becomes a quality metric in its own right. If an investigator asks for the last six months of deviation records, or a specific CAPA's effectiveness check, and it takes your team twenty minutes to locate it in a one-day visit, that's a meaningfully larger share of the available inspection time than it would be in a five-day visit. I'd treat retrieval time the same way I'd treat any other process metric — measure it, and fix it if it's slow.
2. Staff readiness can't be concentrated on a few subject-matter experts. In a longer inspection, if the CAPA lead is out sick on day two, there's usually day three or four to loop them back in. A one-day assessment typically doesn't offer that buffer. Cross-training your quality team so that more than one person can speak fluently to CAPA, complaint handling, and document control isn't optional anymore — it's the difference between a smooth visit and a visibly disorganized one.
3. The pre-inspection homework FDA is doing on its end means your own internal audit program needs to be current, not aspirational. If FDA is selecting facilities and scoping visits based on risk signals — import alerts, complaint databases, prior 483 history, MDR or MedWatch trends — then your internal audit program should be looking at those same signals before FDA does. A facility that already knows where its own weak spots are walks into a one-day assessment in a completely different position than one that's hoping the investigator doesn't ask about the thing everyone's been meaning to fix.

None of this is really new advice. It's the same discipline that's always separated a facility that handles inspections well from one that doesn't. What's changed is the margin for error. A format built around limited hours simply removes the cushion that used to absorb a slow document search or an unprepared floor supervisor.

How I'd Prepare Differently for a Shorter Visit

If I were advising a client on this today, I'd focus preparation on three things specifically, because I think they're the areas most exposed by a compressed inspection window:

1. Run a mock inspection that's actually timed to one day, not open-ended. Most mock inspections I've seen run loose because there's no artificial deadline pressuring the team the way a real one-day assessment would. Time-box it.
2. Audit your CAPA closure documentation specifically for completeness and effectiveness-check evidence, since CAPA is one of the systems most likely to be the sole focus of a narrowly scoped visit — it's high-yield for an investigator because a broken CAPA system tends to reveal broken everything-else.
3. Make sure whoever greets the investigator at the door knows how to scope the visit conversation early. Asking "what would you like to focus on today" isn't evasive — it's a reasonable question that helps your team direct the right people and the right records to the room in the first ten minutes instead of the first two hours.

Our FDA inspection preparation work with clients has always centered on exactly this kind of readiness — not because the goal is to pass an inspection cosmetically, but because a facility that can produce its own records fast and explain its own decisions clearly is usually a facility whose quality system is actually working. A shorter inspection format just makes that underlying truth more visible, faster.

If the Visit Still Produces a 483

A one-day assessment can still end the same way a longer one does: with a Form FDA 483 in hand and a fifteen-business-day clock running before FDA typically expects a written response for a discretionary warning letter decision. That clock doesn't get longer because the inspection was shorter. If anything, I'd argue the response needs to be tighter, because a narrowly scoped inspection produces a narrowly scoped 483 — which means less room to argue that an observation was taken out of broader context. We've written in detail about how to structure that response, including timeline and template guidance, in how to respond to an FDA Form 483.

The Bottom Line

FDA's one-day inspectional assessment is a resource-allocation decision dressed up as a scheduling change. The agency has a fixed number of investigator hours and a growing number of facilities it's responsible for covering under Section 704 authority and the risk-based scheduling mandate FDASIA put in place back in 2012. Compressing the visit is how FDA touches more facilities without adding headcount. For your facility, the compression doesn't lower the bar — it just removes the time you used to have to clear it gracefully.

I don't think this pilot should change what a good quality system looks like. It should change how fast you can prove you have one.

Frequently Asked Questions

What is a one-day inspectional assessment? It's a newly piloted FDA inspection format, announced in the agency's press release on one-day inspectional assessments, that compresses the on-site inspection window to a single day while operating under the same Section 704 FD&C Act authority as traditional inspections. It's intended to let FDA cover more facilities with existing inspectional resources.

Does a one-day assessment replace the traditional multi-day inspection? No. FDA has described it as an addition to its existing inspection toolkit — surveillance inspections, pre-approval inspections, and for-cause inspections all continue. The one-day format appears intended for situations where a narrower, targeted review is appropriate.

Can a one-day inspection still result in a Form FDA 483 or a warning letter? Yes. The classification framework — No Action Indicated, Voluntary Action Indicated, or Official Action Indicated — applies regardless of inspection length, and a 483 can be issued under Section 704(b) whenever an investigator observes conditions that may constitute violations.

Should my facility prepare differently for a shorter inspection than a longer one? I'd say yes, in emphasis if not in substance. The core preparation — accurate records, trained staff, closed-loop CAPA — doesn't change. What changes is how quickly your team needs to locate and explain that evidence, since a one-day visit removes the informal buffer time a multi-day inspection often allows.

Where can I read FDA's original announcement? FDA's press release, "FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight," is available directly on FDA.gov and is the primary source for this article.

Last updated: 2026-09-09